Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue
Daniel Heudobler, Michael Rechenmacher, Florian Lüke, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 11, pp. 3540-3540
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
Hong Fan, Shijia Pan, Guo Yuan, et al.
Molecules (2019) Vol. 24, Iss. 14, pp. 2545-2545
Open Access | Times Cited: 187
Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis
Jiao Feng, Weiqi Dai, Yuqing Mao, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 168
PPAR-α Modulators as Current and Potential Cancer Treatments
Yan Tan, Mina Wang, Yang Ke, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 112
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution
Federica Francescangeli, Maria Laura De Angelis, Rachele Rossi, et al.
Cancer and Metastasis Reviews (2023)
Open Access | Times Cited: 44
Therapeutic potential of PPARγ natural agonists in liver diseases
Liwei Wu, Chuanyong Guo, Jianye Wu
Journal of Cellular and Molecular Medicine (2020) Vol. 24, Iss. 5, pp. 2736-2748
Open Access | Times Cited: 93
PPAR-γ Modulators as Current and Potential Cancer Treatments
Tiange Chi, Mina Wang, Xu Wang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 87
PPAR-γ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer
Sangeeta Ballav, Bini Biswas, Vishal Kumar Sahu, et al.
Cells (2022) Vol. 11, Iss. 20, pp. 3215-3215
Open Access | Times Cited: 29
The role of peroxisome proliferator-activated receptors in the tumor microenvironment, tumor cell metabolism, and anticancer therapy
Jiaao Sun, Liyan Yu, Xueling Qu, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 19
SIRT1/PGC-1α/PPAR-γ Correlate With Hypoxia-Induced Chemoresistance in Non-Small Cell Lung Cancer
Rui Xu, Xin Luo, Xuan Ye, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 36
Peroxisome proliferator‐activated receptors as therapeutic target for cancer
Yuqing Wang, Feifei Lei, Yiyun Lin, et al.
Journal of Cellular and Molecular Medicine (2023) Vol. 28, Iss. 5
Open Access | Times Cited: 16
Nano-ZrO2-Catalyzed Biginelli Reaction and the Synthesis of Bioactive Dihydropyrimidinones That Targets PPAR-γ in Human Breast Cancer Cells
Suresha N. Deveshegowda, Ji-Rui Yang, Xi Zhang, et al.
Catalysts (2023) Vol. 13, Iss. 2, pp. 228-228
Open Access | Times Cited: 12
The Cannabidiol Analog PECS-101 Prevents Chemotherapy-Induced Neuropathic Pain via PPARγ Receptors
Nicole Rodrigues da Silva, Francisco Isaac Fernandes Gomes, Alexandre H. Lopes, et al.
Neurotherapeutics (2021) Vol. 19, Iss. 1, pp. 434-449
Open Access | Times Cited: 25
Targeting mitochondria in dermatological therapy: beyond oxidative damage and skin aging
Tongyu C. Wikramanayake, Jérémy Chéret, Alec Sevilla, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 3, pp. 233-259
Open Access | Times Cited: 18
MEPED as salvage therapy for relapsed/refractory Hodgkin’s lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck
Dennis Christoph Harrer, Florian Lüke, Tobias Pukrop, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Predictive modelling of peroxisome proliferator-activated receptor gamma (PPARγ) IC50 inhibition by emerging pollutants using light gradient boosting machine
Awomuti Adeboye, Zhen Yu, Adesina Odunayo Blessing, et al.
SAR and QSAR in environmental research (2025), pp. 1-23
Closed Access
Activation of PPARs Modulates Signalling Pathways and Expression of Regulatory Genes in Osteoclasts Derived from Human CD14+ Monocytes
Abe Kasonga, Marlena C. Kruger, Magdalena Coetzee
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 7, pp. 1798-1798
Open Access | Times Cited: 29
New Approaches to Cancer Therapy: Combining Fatty Acid Amide Hydrolase (FAAH) Inhibition with Peroxisome Proliferator-Activated Receptors (PPARs) Activation
Leonardo Brunetti, Fulvio Loiodice, Luca Piemontese, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 24, pp. 10995-11003
Closed Access | Times Cited: 29
Treatment of dyslipidemia in kidney transplantation
Claudio Ponticelli, Lorenzo Arnaboldi, Gabriella Moroni, et al.
Expert Opinion on Drug Safety (2020) Vol. 19, Iss. 3, pp. 257-267
Closed Access | Times Cited: 25
Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin
Luana Amorim Biondo, Alexandre Abílio de Souza Teixeira, Karen C. de O. S. Ferreira, et al.
Current Pharmaceutical Design (2020) Vol. 26, Iss. 9, pp. 932-945
Closed Access | Times Cited: 21
Dual PPARγ/ɑ agonist oroxyloside suppresses cell cycle progression by glycolipid metabolism switch-mediated increase of reactive oxygen species levels
Yuxin Zhou, Yongjian Guo, Y. Zhu, et al.
Free Radical Biology and Medicine (2021) Vol. 167, pp. 205-217
Closed Access | Times Cited: 20
Peroxiporins Are Induced upon Oxidative Stress Insult and Are Associated with Oxidative Stress Resistance in Colon Cancer Cell Lines
Ana Čipak Gašparović, Lidija Milković, Claudia Rodrigues, et al.
Antioxidants (2021) Vol. 10, Iss. 11, pp. 1856-1856
Open Access | Times Cited: 20
Nonsteroidal Anti-Inflammatory Drugs as PPARγ Agonists Can Induce PRODH/POX-Dependent Apoptosis in Breast Cancer Cells: New Alternative Pathway in NSAID-Induced Apoptosis
Adam Kazberuk, Magda Chalecka, Jerzy Pałka, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1510-1510
Open Access | Times Cited: 13
Roles of PPAR activation in cancer therapeutic resistance: Implications for combination therapy and drug development
Yanxia Zhang, Bin Xiao, Yunduo Liu, et al.
European Journal of Pharmacology (2023) Vol. 964, pp. 176304-176304
Closed Access | Times Cited: 7
Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis
Daniel Heudobler, Michael Rechenmacher, Florian Lüke, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 22
A novel plausible mechanism of NSAIDs-induced apoptosis in cancer cells: the implication of proline oxidase and peroxisome proliferator-activated receptor
Adam Kazberuk, Ilona Zaręba, Jerzy Pałka, et al.
Pharmacological Reports (2020) Vol. 72, Iss. 5, pp. 1152-1160
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top